Short Interest in Horizon Pharma PLC (NASDAQ:HZNP) Declines By 10.2%

Horizon Pharma PLC (NASDAQ:HZNP) saw a significant decrease in short interest during the month of October. As of October 13th, there was short interest totalling 14,756,238 shares, a decrease of 10.2% from the September 29th total of 16,439,956 shares. Approximately 9.1% of the shares of the company are sold short. Based on an average daily volume of 2,426,334 shares, the days-to-cover ratio is currently 6.1 days.

Shares of Horizon Pharma PLC (NASDAQ HZNP) traded up $0.32 during trading hours on Friday, reaching $13.57. The company had a trading volume of 2,833,700 shares, compared to its average volume of 3,526,486. Horizon Pharma PLC has a twelve month low of $9.45 and a twelve month high of $21.98. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.46 and a current ratio of 1.64. The company has a market cap of $2,171.49, a price-to-earnings ratio of 9.60, a P/E/G ratio of 1.12 and a beta of 1.32.

Horizon Pharma PLC (NASDAQ:HZNP) last posted its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.04. Horizon Pharma PLC had a positive return on equity of 20.22% and a negative net margin of 45.28%. The firm had revenue of $271.60 million during the quarter, compared to analyst estimates of $259.74 million. During the same period last year, the company posted $0.70 EPS. The business’s quarterly revenue was up 30.1% on a year-over-year basis. equities analysts anticipate that Horizon Pharma PLC will post 0.72 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN grew its stake in shares of Horizon Pharma PLC by 24.8% in the 3rd quarter. Wells Fargo & Company MN now owns 456,169 shares of the biopharmaceutical company’s stock valued at $5,784,000 after buying an additional 90,692 shares during the period. Legal & General Group Plc grew its stake in shares of Horizon Pharma PLC by 12.9% in the 3rd quarter. Legal & General Group Plc now owns 63,843 shares of the biopharmaceutical company’s stock valued at $809,000 after buying an additional 7,291 shares during the period. ETRADE Capital Management LLC acquired a new stake in shares of Horizon Pharma PLC in the 3rd quarter valued at about $641,000. American International Group Inc. grew its stake in shares of Horizon Pharma PLC by 8.1% in the 3rd quarter. American International Group Inc. now owns 109,477 shares of the biopharmaceutical company’s stock valued at $1,388,000 after buying an additional 8,185 shares during the period. Finally, Rothschild Asset Management Inc. grew its stake in shares of Horizon Pharma PLC by 22.4% in the 3rd quarter. Rothschild Asset Management Inc. now owns 1,807,129 shares of the biopharmaceutical company’s stock valued at $22,914,000 after buying an additional 330,424 shares during the period. Institutional investors own 82.56% of the company’s stock.

HZNP has been the topic of several research reports. Zacks Investment Research downgraded Horizon Pharma PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Piper Jaffray Companies set a $17.00 target price on Horizon Pharma PLC and gave the company a “buy” rating in a research report on Tuesday, July 25th. Cantor Fitzgerald set a $13.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Monday, July 31st. UBS AG set a $16.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, Mizuho reissued a “hold” rating and set a $12.00 price target (up previously from $9.00) on shares of Horizon Pharma PLC in a research report on Monday, August 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company’s stock. Horizon Pharma PLC has a consensus rating of “Buy” and an average price target of $18.42.

TRADEMARK VIOLATION WARNING: “Short Interest in Horizon Pharma PLC (NASDAQ:HZNP) Declines By 10.2%” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/11/short-interest-in-horizon-pharma-plc-hznp-decreases-by-10-2.html.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply